Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

49.0K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
49.0K
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

164
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
164
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

391
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
391
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

3.0K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
3.0K
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

5.1K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
5.1K
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

124
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
124

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fatty Pancreas and Risk of Type 2 Diabetes, Chronic Kidney Disease and Cardiovascular Events: Evidence From a Population-Based Cohort.

United European gastroenterology journal·2026
Same author

Correction: Lumen-apposing metal stents vs. self-expandable metal stents for endoscopic ultrasound-guided choledochoduodenostomy: a network meta-analysis of randomized controlled trials.

Endoscopy·2026
Same author

Special Populations: Hepatocellular Carcinoma Risk and Liver Transplantation.

Clinics in liver disease·2026
Same author

MARCO promotes cholangiocarcinogenesis by inducing immunosuppression and its targeting reduces tumor growth.

Signal transduction and targeted therapy·2026
Same author

Lumen-apposing metal stents vs. self-expandable metal stents for endoscopic ultrasound-guided choledochoduodenostomy: a network meta-analysis of randomized controlled trials.

Endoscopy·2026
Same author

Gastroscope-assisted endoscopic retrograde cholangiopancreatography with duodenal retroversion for management of recurrent biliary stent obstruction in malignant duodenal stricture.

Endoscopy·2026

Related Experiment Video

Updated: Dec 27, 2025

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

16.1K

Postsustained Virological Response Management in Hepatitis C Patients.

Chiara Masetti1, Ana Lleo1,2, Matteo Colombo1,2

  • 1Division of Internal Medicine and Hepatology, Department of Gastroenterology, Humanitas Clinical and Research Center IRCCS, Rozzano, Milan, Italy.

Seminars in Liver Disease
|February 29, 2020
PubMed
Summary

Direct-acting antiviral agents (DAA) offer high cure rates for chronic hepatitis C virus (HCV) infection. Patients with cirrhosis still require lifelong monitoring for liver cancer and portal hypertension complications.

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.6K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.3K

Related Experiment Videos

Last Updated: Dec 27, 2025

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

16.1K
A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.6K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.3K

Area of Science:

  • Hepatology
  • Virology
  • Internal Medicine

Background:

  • Direct-acting antiviral agents (DAA) have transformed chronic hepatitis C virus (HCV) management.
  • High cure rates (>90%) are achievable, even in advanced liver disease.
  • Viral eradication improves survival and reduces hepatic/extrahepatic complications.

Purpose of the Study:

  • To review the long-term implications of HCV cure in patients with advanced liver disease.
  • To highlight the necessity of ongoing surveillance for cirrhosis complications post-HCV eradication.

Main Methods:

  • Review of current literature on DAA therapy for HCV.
  • Analysis of outcomes in patients with sustained virological response.
  • Identification of key complications requiring monitoring in cirrhotic patients.

Main Results:

  • DAA therapy leads to significant improvements in liver function and survival.
  • Patients achieving sustained virological response are cured of HCV.
  • Cirrhosis patients remain at risk for hepatocellular carcinoma and portal hypertension.

Conclusions:

  • While DAA therapy cures HCV, patients with advanced fibrosis/cirrhosis need lifelong surveillance.
  • Monitoring for hepatocellular carcinoma and clinically significant portal hypertension is crucial.
  • Regular follow-up ensures timely management of potential complications in high-risk patients.